Many people living with type 2 diabetes or struggling with weight know the feeling: one treatment suppresses appetite too much, another affects digestion, and a third leaves muscles weaker than before.
So when researchers begin exploring an option that avoids those trade-offs, it naturally attracts attention. A new approach from Sweden may point toward that kind of balance.
A shift toward muscle-based treatment
Instead of adjusting hunger signals between the gut and the brain, the new therapy focuses on the body's primary energy engine — skeletal muscle.
Scientists at Karolinska Institutet and Stockholm University have been testing a tablet designed to raise metabolic activity directly inside muscle cells.
Also read: This is how to cope with anxiety during vaccinations
In animal studies, the drug enhanced blood-sugar regulation and improved fat metabolism without triggering the loss of lean mass seen with many GLP-1 medications.
Early human data echo the positive trend. Volunteers with and without type 2 diabetes tolerated the treatment well, suggesting that a muscle-targeted strategy could become a meaningful alternative to the injection-based therapies currently dominating the field.
Re-engineering a β2 agonist for safety and effect
The compound is a specially developed variant of a β2 agonist — a class of molecules known to influence how muscles use energy.
Traditional versions can overstimulate the heart, but this new form activates signaling pathways in a controlled way, supporting muscle function without placing strain on the cardiovascular system.
Also read: Psychologists propose a new personality orientation called the otrovert
Researchers behind the project also highlight the convenience factor: the medication comes as a pill rather than an injection, potentially making long-term use easier for patients.
And because it encourages healthier weight loss by maintaining muscle, it could address one of the biggest concerns surrounding modern metabolic drugs.
Potential as both standalone and combination therapy
What makes the discovery particularly interesting is that it operates through a mechanism completely separate from GLP-1 drugs like Ozempic.
That means it could stand on its own — or be paired with existing treatments for stronger results.
Also read: Expert identifies common traits in music that boost listeners’ mood
Article based on information from ScienceDaily and Cell
Also read: How science says you can beat the winter blues this year
This article is made and published by Mie Hermansen, who may have used AI in the preparation.